LOGO
LOGO

FDA Calendar - Kura Oncology Inc.

Company Name Kura Oncology Inc.
KURA
Drug Name ziftomenib (NDA)
Event Name FDA decision on ziftomenib for treatment for adult patients with relapsed or refractory acute myeloid leukemia with a nucleophosmin 1 mutation
Event Date 11/30/2025
Outcome Date 11/13/2025
Outcome FDA approved KOMZIFTI (ziftomenib), the first and only once-daily targeted therapy for adults with relapsed or refractory NPM1-Mutated Acute Myeloid Leukaemia on Nov.13, 2025
Drug Status Breakthrough Therapy Designation
Rival Drugs
Market Potential
Other Approvals
News
FDA Reviews Kura's NDA For Ziftomenib To Treat Acute Myeloid Leukemia With NPM1 Mutation
RELATED NEWS (Kura Oncology Inc.)